Jane Street’s PDS Biotechnology PDSB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-36,581
Closed -$36.9K 12060
2025
Q3
$36.9K Sell
36,581
-32,670
-47% -$38.4K ﹤0.01% 10418
2025
Q2
$92.1K Buy
+69,251
New +$94K ﹤0.01% 8987
2025
Q1
Sell
-35,644
Closed -$58.1K 10319
2024
Q4
$58.1K Buy
+35,644
New +$94.3K ﹤0.01% 8930
2024
Q3
Sell
-114,032
Closed -$334K 10193
2024
Q2
$334K Buy
114,032
+38,753
+51% +$124K ﹤0.01% 7639
2024
Q1
$298K Buy
75,279
+54,917
+270% +$283K ﹤0.01% 7578
2023
Q4
$101K Buy
+20,362
New +$101K ﹤0.01% 8573
2023
Q3
Sell
-39,422
Closed -$198K 9183
2023
Q2
$198K Sell
39,422
-84,514
-68% -$553K ﹤0.01% 7682
2023
Q1
$762K Buy
123,936
+92,807
+298% +$759K ﹤0.01% 5545
2022
Q4
$411K Buy
31,129
+7,967
+34% +$56.2K ﹤0.01% 6478
2022
Q3
$69K Buy
+23,162
New +$98.3K ﹤0.01% 8807
2022
Q1
Sell
-19,329
Closed -$157K 10854
2021
Q4
$157K Buy
19,329
+2,590
+15% +$27.9K ﹤0.01% 8975
2021
Q3
$249K Buy
+16,739
New +$209K ﹤0.01% 8517
2018
Q4
Sell
-1,024
Closed -$17K 5503
2018
Q3
$17K Sell
1,024
-2,033
-67% -$36.5K ﹤0.01% 4977
2018
Q2
$63K Buy
+3,057
New +$63.8K ﹤0.01% 4795

Other funds holding PDSB

Jane Street's PDSB Position: Q4 2025 in Review

Jane Street sold out of PDS Biotechnology (PDSB) in Q4 2025, closing a stake of 36,581 shares — an estimated $36.9K sold.

Jane Street first reported a position in PDSB in Q2 2018 and held it in 14 quarters. The position peaked at $762K in Q1 2023. 44 funds tracked by Wall St. Rank hold PDSB as of Q4 2025.

  • Jane Street reported no remaining PDS Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 36,581 PDS Biotechnology shares in Q4 2025, an estimated $36.9K.
  • Jane Street first reported a position in PDS Biotechnology in Q2 2018 and held it in 14 quarters.
  • Jane Street's PDS Biotechnology position peaked at $762K in Q1 2023.
  • 44 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.